Altria Group reported fourth‑quarter 2025 results that showed net revenues of $5.08 billion, a 0.5% decline year‑over‑year, and adjusted diluted earnings per share of $1.30, unchanged from the same quarter a year earlier. Adjusted operating‑cost‑included margins rose to 63.4%, an improvement of 1.8 percentage points over the prior year’s 61.6%.
The revenue dip was driven by a 7.9% drop in domestic cigarette shipment volume, the core driver of Altria’s legacy business. The decline was partially offset by a 2.0% increase in oral tobacco revenue, but the net effect was a modest revenue contraction. Pricing power in the smokeable segment helped keep margins healthy despite the volume decline, while the company’s cost‑control initiatives maintained profitability.
Altria’s adjusted diluted EPS of $1.30 fell short of the consensus estimate of $1.32, a miss of $0.02 per share. The miss reflects the impact of a $1.3 billion impairment charge on the e‑vapor segment in Q4 and a $2.2 billion charge for the full year, which were excluded from adjusted results but indicate the cost of the company’s transition to smoke‑free products. Nevertheless, the company’s pricing strategy and operational leverage helped keep the EPS close to expectations.
For 2026, Altria guided full‑year adjusted diluted EPS of $5.56 to $5.72, a 2.5% to 5.5% increase over the 2025 figure of $5.42. Management said the guidance reflects continued pricing power in the smokeable segment, ongoing investment in the smoke‑free portfolio, and confidence in the company’s long‑term transition strategy. CEO Billy Gifford noted that “the Smokeable Products segment delivered over $11 billion in adjusted OCI for the full year and expanded adjusted OCI margins by 1.8 percentage points to 63.4%,” underscoring the company’s focus on margin expansion.
Investors reacted cautiously, weighing the EPS miss against the company’s guidance and the persistent decline in cigarette volumes. The guidance signals management’s confidence in maintaining profitability while the company continues to invest in its smoke‑free portfolio, a key growth area as cigarette volumes continue to fall.
Altria’s strategic shift toward smoke‑free products is reinforced by the acquisition of NJOY and the ongoing development of oral nicotine pouches and e‑vapor offerings. The company’s impairment charges highlight the upfront costs of this transition, but the company remains committed to a high dividend yield and share‑repurchase program, which support shareholder returns amid the evolving nicotine market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.